252 related articles for article (PubMed ID: 10527073)
1. Antitumor effect of vaccinia virus in glioma model.
Timiryasova TM; Li J; Chen B; Chong D; Langridge WH; Gridley DS; Fodor I
Oncol Res; 1999; 11(3):133-44. PubMed ID: 10527073
[TBL] [Abstract][Full Text] [Related]
2. Replication-deficient vaccinia virus gene therpay vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells.
Timiryasova TM; Chen B; Fodor I
J Gene Med; 2001; 3(5):468-77. PubMed ID: 11601760
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model.
Chen B; Timiryasova TM; Andres ML; Kajioka EH; Dutta-Roy R; Gridley DS; Fodor I
Cancer Gene Ther; 2000 Nov; 7(11):1437-47. PubMed ID: 11129286
[TBL] [Abstract][Full Text] [Related]
4. Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model.
Fodor I; Timiryasova T; Denes B; Yoshida J; Ruckle H; Lilly M
J Urol; 2005 Feb; 173(2):604-9. PubMed ID: 15643273
[TBL] [Abstract][Full Text] [Related]
5. Intracerebral adenovirus-mediated p53 tumor suppressor gene therapy for experimental human glioma.
Li H; Alonso-Vanegas M; Colicos MA; Jung SS; Lochmuller H; Sadikot AF; Snipes GJ; Seth P; Karpati G; Nalbantoglu J
Clin Cancer Res; 1999 Mar; 5(3):637-42. PubMed ID: 10100717
[TBL] [Abstract][Full Text] [Related]
6. Radiation enhances the anti-tumor effects of vaccinia-p53 gene therapy in glioma.
Timiryasova TM; Gridley DS; Chen B; Andres ML; Dutta-Roy R; Miller G; Bayeta EJ; Fodor I
Technol Cancer Res Treat; 2003 Jun; 2(3):223-35. PubMed ID: 12779353
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Lun XQ; Jang JH; Tang N; Deng H; Head R; Bell JC; Stojdl DF; Nutt CL; Senger DL; Forsyth PA; McCart JA
Clin Cancer Res; 2009 Apr; 15(8):2777-88. PubMed ID: 19351762
[TBL] [Abstract][Full Text] [Related]
8. Oncolytic activity of p53-expressing conditionally replicative adenovirus AdDelta24-p53 against human malignant glioma.
Geoerger B; Vassal G; Opolon P; Dirven CM; Morizet J; Laudani L; Grill J; Giaccone G; Vandertop WP; Gerritsen WR; van Beusechem VW
Cancer Res; 2004 Aug; 64(16):5753-9. PubMed ID: 15313916
[TBL] [Abstract][Full Text] [Related]
9. Attenuation of a vaccine strain of vaccinia virus via inactivation of interferon viroceptor.
Dénes B; Gridley DS; Fodor N; Takátsy Z; Timiryasova TM; Fodor I
J Gene Med; 2006 Jul; 8(7):814-23. PubMed ID: 16634110
[TBL] [Abstract][Full Text] [Related]
10. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant.
Puhlmann M; Brown CK; Gnant M; Huang J; Libutti SK; Alexander HR; Bartlett DL
Cancer Gene Ther; 2000 Jan; 7(1):66-73. PubMed ID: 10678358
[TBL] [Abstract][Full Text] [Related]
11. Antitumor effect of IL-2, p53, and bax gene transfer in C6 glioma cells.
Haghighat P; Timiryasova TM; Chen B; Kajioka EH; Gridley DS; Fodor I
Anticancer Res; 2000; 20(3A):1337-42. PubMed ID: 10928041
[TBL] [Abstract][Full Text] [Related]
12. Low-dose vaccinia virus-mediated cytokine gene therapy of glioma.
Chen B; Timiryasova TM; Haghighat P; Andres ML; Kajioka EH; Dutta-Roy R; Gridley DS; Fodor I
J Immunother; 2001; 24(1):46-57. PubMed ID: 11211148
[TBL] [Abstract][Full Text] [Related]
13. Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo.
Jacobs A; Tjuvajev JG; Dubrovin M; Akhurst T; Balatoni J; Beattie B; Joshi R; Finn R; Larson SM; Herrlinger U; Pechan PA; Chiocca EA; Breakefield XO; Blasberg RG
Cancer Res; 2001 Apr; 61(7):2983-95. PubMed ID: 11306477
[TBL] [Abstract][Full Text] [Related]
14. Bystander effect-mediated gene therapy of gliomas using genetically engineered neural stem cells.
Li S; Tokuyama T; Yamamoto J; Koide M; Yokota N; Namba H
Cancer Gene Ther; 2005 Jul; 12(7):600-7. PubMed ID: 15775995
[TBL] [Abstract][Full Text] [Related]
15. [Effects of CPUY013, a novel Topo I inhibitor, on human gastric adenocarcinoma BGC823 cells in vitro and in vivo].
Ji YB; Zhou JH; Zuo MX; You QD
Yao Xue Xue Bao; 2008 Aug; 43(8):811-8. PubMed ID: 18956773
[TBL] [Abstract][Full Text] [Related]
16. Vaccinia virus CrmE encodes a soluble and cell surface tumor necrosis factor receptor that contributes to virus virulence.
Reading PC; Khanna A; Smith GL
Virology; 2002 Jan; 292(2):285-98. PubMed ID: 11878931
[TBL] [Abstract][Full Text] [Related]
17. Expression of p53, or targeting towards EGFR, enhances the oncolytic potency of conditionally replicative adenovirus against neuroblastoma.
Geoerger B; van Beusechem VW; Opolon P; Morizet J; Laudani L; Lecluse Y; Barrois M; Idema S; Grill J; Gerritsen WR; Vassal G
J Gene Med; 2005 May; 7(5):584-94. PubMed ID: 15651070
[TBL] [Abstract][Full Text] [Related]
18. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2.
Guo ZS; Naik A; O'Malley ME; Popovic P; Demarco R; Hu Y; Yin X; Yang S; Zeh HJ; Moss B; Lotze MT; Bartlett DL
Cancer Res; 2005 Nov; 65(21):9991-8. PubMed ID: 16267024
[TBL] [Abstract][Full Text] [Related]
19. Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas.
Lun X; Senger DL; Alain T; Oprea A; Parato K; Stojdl D; Lichty B; Power A; Johnston RN; Hamilton M; Parney I; Bell JC; Forsyth PA
J Natl Cancer Inst; 2006 Nov; 98(21):1546-57. PubMed ID: 17077357
[TBL] [Abstract][Full Text] [Related]
20. Targeted-simultaneous expression of Gas1 and p53 using a bicistronic adenoviral vector in gliomas.
Benítez JA; Arregui L; Vergara P; Segovia J
Cancer Gene Ther; 2007 Oct; 14(10):836-46. PubMed ID: 17599090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
